Board to approve September 2026 quarterly and half-year results

Results View source PDF Explain this filing

AMBALALSA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-1.0%Reaction day

₹35.60

prior close

—

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is usedpendingvs market: pending

Pharmaceuticals peers, median of 171sector+0.4%-1.3% vs sector

On the reaction day the stock moved 1.3 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

—

10m

—

15m

—

30m

—

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-1.0pendingpending+0.4-1.3

Next day

—————

15d

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 171Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

The board will meet on November 5, 2026 to approve unaudited standalone and consolidated results for the quarter and half-year ended September 30, 2026, along with the auditors' limited review. The trading window is closed from October 1 through November 7.

Likely market impact

No earnings figures or profit outlook were provided. The results may affect investor sentiment, while the trading window remains closed through November 7.